Ropinirole News
NovaDel Announces Two CNS Oral Spray Drug Candidates in its Development Pipeline; Oral Spray Formulations of Tizanidine for Spasticity and Ropinirole for Parkinson's Disease
Flemington, N.J.-- NovaDel Pharma today announced the two latest additions to its pipeline of oral spray drug development candidates.
Study Reveals Investigational 24-Hour Formulation of Ropinirole Hcl Tablets Reduced "Off" Time for Patients With Parkinson's Disease
Average Awake Time Spent "Off" Decreased by 2.1 Hours per Day
Adartrel Is First Restless Legs Syndrome Treatment To Receive A Positive Decision From The European Commission
GlaxoSmithKline (GSK) announced today that the European Commission has adopted a positive decision on the marketing authorisation application for Adartrel® (ropinirole) for the treatment of moderate to severe idiopathic RLS...
Requip (Ropinirole HCl) Tablets Significantly Improve Symptoms of Restless Legs Syndrome
Largest U.S. Study in Moderate-to-Severe Primary RLS Published in Mayo Clinic Proceedings
Parkinson's Disease - initiating patients on Ropinirole delivers long-term benefits
Data announced today at the 16th International Congress on Parkinson's Disease and Related Disorders (ICPD) in Berlin, show that initiating treatment with ropinirole (versus L-dopa) is associated with lower incidence, and delayed...
Displaying results 6 to 10 out of 12